Novo Nordisk and Sanofi to cut Insulin prices, following moves by Eli Lilly
March 2023
Novo Nordisk to cut U.S. list prices for several insulin products by up to 75% next year. Sanofi announced that it will cut prices by 78%. Effective January 1st, 2024.
Generally plans will see 1%-2% total plan cost reduction from this price improvement. Please contact CCRx to discuss possible copay or benefit plan changes for 2024 in light of these price reductions.
Losing patent protection 2023
March 2023
Some brand drugs losing patent protection in 2023 include: Stelara, Vyvanse, Aubagio, Livalo, Actemra, Symbicort, Trokendi XR, and Myrbetriq.
Please reach your contact at CCRx with any questions, or to discuss in more detail.
Recent Newsletters
What Is The Right Copay Strategy?
What Is The Right Copay Strategy? January 2024Crystal Clear Rx clients know that effectively managing the pharmacy benefit involves more than just PBM pricing. Utilization, Drug Mix, and Plan Design also impact the amount of money the Plan spends on their pharmacy...
The “Skinny” on Weight Loss Drugs
The “Skinny” on Weight Loss Drugs November 2023A lot of attention has been given lately to a new class of drugs called GLP-1’s. These drugs are increasingly being prescribed for type 2 diabetes and weight loss. Most Crystal Clear Rx clients cover these drugs for...
What to look for in a pharmacy benefit consultant
What to look for in a Pharmacy Benefit Consultant November 21, 2023Nobody wants to pay more than they should for any product or service. So, when many companies become concerned over pharmacy benefit costs, they may look for a Pharmacy Benefits Consultant or firm who...
Walgreens and CVS pharmacist Walk-outs
Walgreens and CVS pharmacist Walk-outs October 30th, 2023You may have recently seen news stories regarding pharmacist walk-outs at both Walgreens and CVS, and the potential for further work stoppages in the future at both of these companies, and potentially at other...
Choosing a PBM
Choosing a PBM September 2023 One of the primary services CCRx offers prospective clients is to assist them in the selection of a new pharmacy benefit manager, or PBM. Sometimes we are asked to utilize a Request for Proposal (RFP) process to narrow down the field of...
Effective Prior Authorization Management
Effective Prior Authorization Management August 2023 The effective management of the Prior Authorization (PA) function is a crucial aspect of healthcare that ensures patients receive the appropriate medications while controlling costs. Pharmacy Benefit Managers (PBMs)...
Conflict of Interest
Conflict of Interest July 2023 Recently a respected competitor published an article condemning most pharmacy benefit consultants for not disclosing conflicts of interest. They correctly pointed out that many big corporations such as “Boeing and UPS to local school...
New Transparency Models
New Transparency Models May 23, 2023 Both Express Scripts and OptumRx have announced new, optional Pass-Through pricing programs. Their clients can adopt this new pricing strategy, or they can continue with non-transparent pricing where the PBM won’t disclose the true...
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company April 2023 The Mark Cuban Cost Plus Drug Company has announced that they have entered into a contract with JanssenUS, a subsidiary of Johnson and Johnson, to distribute Invokana, an important...
Senators introduced bills to reform PBMs and create new FTC probe
Senators introduced bills to reform PBMs and create new FTC probe February 2023 U.S. Senator Cantwell (D-Wash) recently re-introduced the Pharmacy Benefit Manager Transparency Act of 2022 which was previously co-sponsored by herself and Senator Grassley (R-Iowa). The...